Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-25-024457
Filing Date
2025-03-17
Accepted
2025-03-17 16:33:31
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B5 tm259263d1_424b5.htm 424B5 328360
2 GRAPHIC image_002.jpg GRAPHIC 5238
3 GRAPHIC tm2121220d1_424b5img002.jpg GRAPHIC 41847
4 GRAPHIC tm2212977d1_s3sp1.jpg GRAPHIC 11565
  Complete submission text file 0001104659-25-024457.txt   410825
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-264394 | Film No.: 25745043
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)